| Document |
Document Title |
|
WO/2023/021472A1 |
In one embodiment, the present invention describes a method for identifying an optimized natural medicine containing defined doses of active and contributing ingredients. In one embodiment, the method disclosed in the present invention d...
|
|
WO/2023/021024A1 |
The present invention relates to the treatment of cancer by administering thermosensitive liposomes comprising doxorubicin. The liposome administration may preferably be combined with hyperthermia before, during and/or after the liposome...
|
|
WO/2023/020290A1 |
A polypeptide derived from dry-cured ham and capable of alleviating alcoholic liver damage, and a preparation method therefor, wherein the amino acid sequence is Lys-Arg-Gln-Lys-Tyr-Asp. The active peptide has the functions of improving ...
|
|
WO/2023/020486A1 |
Provided are a receptor-interacting protein-1 ("RIP1") kinase inhibitor compound as shown in formula (I), or a stereoisomer, tautomer, deuterated substance, nitrogen oxide, solvate or pharmaceutically acceptable salt thereof, a pharmaceu...
|
|
WO/2023/021140A1 |
The present invention provides a Bifidobacterium lactis supernatant for use in enhancing expression of anti-inflammatory cytokines and/or reducing expression of pro-inflammatory chemokines in the gastrointestinal tract of a subject havin...
|
|
WO/2023/022244A1 |
The present invention relates to a composition for protecting the liver or preventing or improving liver disease, comprising, as an active ingredient, a combination of Schisandra chinensis extract and Hoveni dulcis Thunb. extract, which ...
|
|
WO/2023/020831A1 |
Disclosed are compositions comprising pasteurized Akkermansia for the treatment or prevention of gut contractility disorders, in particular for reducing the duodenal amplitude of contractions.
|
|
WO/2023/022623A1 |
The invention relates to the chemistry of biologically active compounds, and more particularly to an agent containing a derivative of a series of natural porphyrins of formula (1) and lipids for forming a liposomal form or an emulsion. T...
|
|
WO/2023/022106A1 |
The purpose of the present invention is to provide an intestinal regulator which can be provided at low cost while having good intestinal action, is easily adopted despite generally belonging to the field of livestock, in which cost effe...
|
|
WO/2023/022078A1 |
The purpose of the present invention is to provide tablets which contain magnesium oxide particles capable of achieving both of the reduction in friability and the reduction in a capping occurrence rate as a main component.　Provided ar...
|
|
WO/2023/021141A1 |
The present invention provides use of a Bifidobacterium lactis supernatant as a bifidogenic factor. The present invention also provides a Bifidobacterium lactis supernatant for use in enhancing the growth of bifidobacteria in the gastroi...
|
|
WO/2023/019461A1 |
A composition for improving liver function damage and the use thereof. The composition comprises the following components: citrus flavonoid, citrus fiber and fructooligosaccharide. The combined use of citrus flavonoid, citrus fiber and f...
|
|
WO/2023/019949A1 |
Disclosed is the use of a nitrate and vitamin C microcapsule in the preparation of a drug for treating sicca syndrome. The microcapsule comprises a wall material and a core material encapsulated in the wall material, wherein the core mat...
|
|
WO/2023/023184A1 |
Provided are biomarkers for parenteral nutrition associated cholestasis (PNAC) in subjects, especially infants receiving parenteral nutrition (PN). Using such biomarkers provide methods of diagnosing and/or assessing risk of PNAC in a su...
|
|
WO/2023/019950A1 |
A microcapsule containing vitamin C and nitrate, said capsule comprising a wall material and a core material encapsulated in the wall material. The wall material comprises pectin and sodium carboxymethyl cellulose, and the core material ...
|
|
WO/2023/022522A1 |
The present disclosure relates to a pharmaceutical preparation for treating or preventing steatohepatitis, steatosis and/or fibrosis, containing two active ingredients. The present disclosure relates to a complex preparation. The present...
|
|
WO/2023/019084A1 |
Disclosed herein is a method of modifying one or more measures of gastric function in an individual, namely, increasing gastric accommodation, delaying satiety, and accelerating gastric emptying by administering the NK-1 receptor antagon...
|
|
WO/2023/019215A1 |
Provided herein are multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases.
|
|
WO/2023/018972A1 |
Various methods and compositions for using udenafil, or a pharmaceutical acceptable salt thereof, for improving enhanced liver fibrosis (ELF) score for improving, maintaining/stabilizing, preventing and/or reducing the rate of decline of...
|
|
WO/2023/016505A1 |
Provided is an antibody or an antigen-binding fragment thereof capable of specifically recognizing IL-11. The antibody comprises heavy chain variable region CDRs as shown in SEQ ID NOs: 4-6, light chain variable region CDRs as shown in S...
|
|
WO/2023/017452A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis...
|
|
WO/2023/018649A1 |
The present disclosure relates generally to formulations for gastric and gastroesophageal disorders, such as gastroesophageal reflux disorder (GERD) acid reflux, peptic ulceration, acute and/or chronic gastritis, and other disorders, and...
|
|
WO/2023/017370A1 |
A composition in dry powder form for inhalation comprising: (i) a mixture M that comprises or, alternatively, consists of hyaluronic acid or an acceptable pharmaceutical grade salt thereof and, optionally, (ii) at least one acceptable ph...
|
|
WO/2023/016319A1 |
Provided are a crystal form of Lanifibranor (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of pan-PPAR ...
|
|
WO/2023/016950A1 |
There is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in a method of treatment of fatty liver disease or hepatocellular carcinoma (HCC).
|
|
WO/2023/017316A1 |
Provided herein are compositions of anorectal transition zone stem cells, including multipotent and progenitor cells, to treat anal fistulas, for example, refractory complex perianal fistulas associated with Crohn's disease or of unknown...
|
|
WO/2023/016246A1 |
Provided are a method for rapidly inducing the differentiation of mesenchymal stem cells, a kit, and an application thereof. The provided method for rapidly inducing the differentiation of mesenchymal stem cells can produce a sufficient ...
|
|
WO/2023/015944A1 |
The present invention relates to a compound as represented by formula I and a racemate, stereoisomer, tautomer, isotope labeled substance, solvate, polymorph, ester, prodrug or pharmaceutically acceptable salt thereof, a pharmaceutical c...
|
|
WO/2023/017451A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to antagonise the Stimulator of Interferon Genes (STING) protein and may thereby treat liver fibrosis, fatty liver disease, non-alcoholic steatohepatitis...
|
|
WO/2023/014048A1 |
The present invention relates to a novel microorganism, a lysate thereof, a culture medium, an extract of the culture medium, vesicles, and anti-inflammatory and/or antibacterial uses thereof. A novel strain and vesicles derived therefro...
|
|
WO/2023/015269A1 |
Administration of aquaporin-1 (AQP1) complementary deoxyribonucleic acid (cDNA) to a salivary gland prior to treatment with ionizing radiation (IR) prevents the subsequent IR-induced loss in function. The administration of AQP1 (e.g., hu...
|
|
WO/2023/014049A1 |
The present invention relates to a novel pyrrolopyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising same as an active ingredient for prevention or treatment of metabolic liver diseas...
|
|
WO/2023/014070A1 |
The present invention relates to a pharmaceutical composition for preventing or treating liver diseases, comprising, as an active ingredient, STC-1 or a derivative thereof. A STC-1 protein according to the present invention reduces, in a...
|
|
WO/2023/012540A1 |
The present invention relates to a protein belonging to the S100 family for use in the treatment or amelioration of diseases such as ulcerative colitis, Crohn's disease, IBD, neurological disorders, cardiovascular diseases, oncological d...
|
|
WO/2023/014054A1 |
The present invention relates to a novel microorganism, a lysate thereof, a culture medium, an extract of the culture medium, a vesicle, and anti-inflammatory and/or antibacterial uses thereof. A novel strain and a vesicle derived theref...
|
|
WO/2023/011359A1 |
A bridged ring compound and the use thereof in the preparation of a drug for treating related diseases. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/011276A1 |
The present invention relates to the technical field of biomedicine, particularly to a class of CDDO/tetramethylpyrazine alcohol heterocomplexes having a combination therapy effect, and a preparation method therefor and the use thereof, ...
|
|
WO/2023/011635A1 |
The use of montelukast or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an immunodeficiency disorder and also for the treatment of a disorder characterized by inflammation in a patien...
|
|
WO/2023/011301A1 |
The present invention provides a JAK inhibitor having high oral bioavailability, characterized in that the JAK inhibitor comprises: a formula I compound, or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, or pharmaceuticall...
|
|
WO/2023/008555A1 |
The present invention provides a therapeutic agent for ischemic diseases, the therapeutic agent comprising an apoptosis inhibitor of macrophage (AIM), an AIM fragment having a biological activity of the AIM, or a nucleic acid encoding th...
|
|
WO/2023/007185A1 |
The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, and/or N-oxide thereof. The invention also relates to the processes for the preparation of those...
|
|
WO/2023/007766A1 |
Provided is a pharmaceutical composition with which an adequate constipation treatment success rate is achieved in pediatric constipation patients aged 1 to 5. The pharmaceutical composition is for treating constipation and contains magn...
|
|
WO/2023/010049A1 |
Compositions and methods are provided for the treatment of one or both of type 2 diabetes and fatty liver disease, e.g. non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The adipokine Isthmin-1 (ISM1) pro...
|
|
WO/2023/006765A1 |
Methods of treating or preventing alcoholic liver disease are disclosed, the methods comprising administering to a subject a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-me...
|
|
WO/2023/008472A1 |
The present invention provides a benzothiazole derivative represented by formula (I) (in the formula, A1, L and Q are as defined in the description) or a pharmaceutically acceptable salt thereof, which exhibits a DYRK inhibitory activity...
|
|
WO/2023/008553A1 |
The purpose of the present invention is to provide a new molecule neutralizing bonding between ACE2 and the RBD of the spike protein of a corona virus variant. The present invention provides a chicken antibody binding to the spike protei...
|
|
WO/2023/008919A1 |
The present invention relates to a pharmaceutical composition and a functional food composition, each including a benzylaminoethanol derivative as an active ingredient, for prevention or treatment of metabolic disease. The composition of...
|
|
WO/2023/006857A1 |
The present invention relates to a combination product containing, as active ingredients, at least desmodium, Californian poppy, magnesium and vitamin B6 for stimulating liver cell function and promoting sleep.
|
|
WO/2023/007184A1 |
The present invention relates to compounds of Formulae (IA), (IB), (IIA), and (IIB) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The invention also relates to the pro...
|
|
WO/2023/008879A1 |
The present invention relates to an oral composition comprising an Aucuba japonica extract and superoxide dismutase (SOD) and/or Bacillus strain spores and a use thereof for improving oral health or managing oral hygiene. This compositio...
|
